CORRECTION FDA Accepts Autolus Therapeutics’ Marketing Application For Obecabtagene Autoleucel For Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia, With Target Action Date Of November 16, 2024
Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the U.S.